131 related articles for article (PubMed ID: 21450154)
1. Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone.
Karayal ON; Anway SD; Batzar E; Vanderburg DG
J Clin Psychiatry; 2011 Mar; 72(3):367-75. PubMed ID: 21450154
[TBL] [Abstract][Full Text] [Related]
2. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
[TBL] [Abstract][Full Text] [Related]
3. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
Pappadopulos E; Newcomer JW; Kolluri S
J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
5. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
6. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
7. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
Citrome L
Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone for maintenance treatment of bipolar I disorder in adults.
Dubovsky SL; Dubovsky AN
Expert Opin Pharmacother; 2011 Apr; 12(5):817-24. PubMed ID: 21385150
[TBL] [Abstract][Full Text] [Related]
11. Possible ziprasidone-induced mania.
Larson MF; Hauser A
J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
[No Abstract] [Full Text] [Related]
12. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
13. The highest intentional ziprasidone overdose was not fatal.
Prieto T; Benabarre A; Bernardo M
Acta Psychiatr Scand; 2005 Jul; 112(1):79-80; author reply 80. PubMed ID: 15952953
[No Abstract] [Full Text] [Related]
14. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
16. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
17. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
[TBL] [Abstract][Full Text] [Related]
18. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder.
Cañas F; Correll CU; Fagiolini A; Larmo I; Levy P; Papageorgiou G; Rossi A; Zink M; Montes JM
Expert Opin Pharmacother; 2011 Oct; 12(14):2245-63. PubMed ID: 21801083
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
